Gilead Sciences and EVOQ Therapeutics have a new 2023 partnership to develop immunotherapies for RA & SLE - using NanoDisc technology with lymph-targeted delivery of disease-specific-antigens. Gilead has IRAK4 inhibitor, GS-5718in Phase I https://t.co/kanUXUhMSm https://t.co/ZaDH1ueWrl